Skip to main content

Adma Biologics, Inc 10-Q for FY2026 Q3

Adma Biologics, Inc. (ADMA)

10-Q 2026-11-04 For: 2026-09-30
View Original
Added on November 04, 2026

About this 10-Q

Adma Biologics, Inc filed this 10-Q on November 4, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

ADMA Biologics reported third-quarter revenue of 141,102 and net income of 49,884, both in thousands, versus 134,224 and 36,428 in the prior-year quarter. Cash and cash equivalents were 124,555, also in thousands. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$141.1M
up 5.1% from $134.22M a year earlier
Net income
$49.88M
up 36.9% from net income of $36.43M a year earlier
Diluted EPS
$0.22
up 46.7% from $0.15 a year earlier